To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

A multicentre, retrospect… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden.

Journal article
Authors Bertil Lindblom
Jean-Philippe Nordmann
Eric Sellem
Enping Chen
R Gold
Werner Polland
W Williamson
Patricia Buchholz
John G Walt
Danielle Groleau
Alistair Curry
Stacy J Evans
Published in Acta ophthalmologica Scandinavica
Volume 84
Issue 1
Pages 74-83
ISSN 1395-3907
Publication year 2006
Published at Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation
Pages 74-83
Language en
Links dx.doi.org/10.1111/j.1600-0420.2005...
Keywords Aged, Antihypertensive Agents, economics, Cost-Benefit Analysis, Drug Costs, Female, France, Glaucoma, Open-Angle, economics, therapy, Health Care Costs, Health Resources, economics, utilization, Humans, Intraocular Pressure, Male, Ocular Hypertension, economics, therapy, Ophthalmologic Surgical Procedures, economics, Retrospective Studies, Sweden
Subject categories Ophtalmiatrics

Abstract

PURPOSE: To assess resource utilization and costs associated with glaucoma management in France and Sweden. METHODS: A total of 267 patient records (121 in France, 146 in Sweden) with diagnoses of primary open-angle glaucoma (POAG) and ocular hypertension (OH), treated medically, were reviewed for a 2-year period (beginning during 1997-99) for relevant clinical and resource utilization data. Economic data were applied to estimate treatment costs. RESULTS: The annual cost of treating glaucoma was estimated at SEK5305 (531 euro )/patient in Sweden and 390 euro/patient in France. In both countries, medication costs comprised about half of the total costs. Surgical procedures and hospitalizations represented greater proportions of total cost in France (7.0% and 9.6%, respectively) than in Sweden (3.7% and 0.6%, respectively). CONCLUSION: Medication costs represent a high proportion of total treatment costs. These findings highlight the relative importance of medical therapy and of assessing the cost-effectiveness of medications in glaucoma.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?